Shuttle Pharmaceuticals Inc Total Liabilities
Shuttle Pharmaceuticals Inc total liabilities. Based on the latest financial reports, Shuttle Pharmaceuticals Inc (SHPH) has total liabilities worth $8.46 Million USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check financial resilience of Shuttle Pharmaceuticals Inc to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Shuttle Pharmaceuticals Inc (2017–2025)
Total liabilities of Shuttle Pharmaceuticals Inc from 2017 to 2025. This chart illustrates how Shuttle Pharmaceuticals Inc's total liabilities have evolved over time, based on quarterly financial data.
Shuttle Pharmaceuticals Inc Competitors by Total Liabilities
The table below lists competitors of Shuttle Pharmaceuticals Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Frontier Developments Plc
LSE:FDEV
|
UK | GBX42.42 Million |
|
Signing Day Sports, Inc.
NYSE MKT:SGN
|
USA | $1.09 Million |
|
Korab Resources Ltd
AU:KOR
|
Australia | AU$4.53 Million |
|
Siti Networks Limited
NSE:SITINET
|
India | Rs24.61 Billion |
|
Chakana Copper Corp
V:PERU
|
Canada | CA$230.65K |
|
ELEMENT NUTR.SCIENCES
F:93X
|
Germany | €6.80 Million |
|
Aker Carbon Capture ASA
OL:ACC
|
Norway | Nkr100.00 Million |
|
Unicorn AIM VCT plc
LSE:UAV
|
UK | GBX2.41 Million |
Liability Composition Analysis (2017–2025)
This chart breaks down Shuttle Pharmaceuticals Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see total assets of Shuttle Pharmaceuticals Inc.
Liquidity & Leverage Metrics
Shuttle Pharmaceuticals Inc Total Liabilities Ratios Explained
Shuttle Pharmaceuticals Inc total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.30 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 2.53 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.72 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Shuttle Pharmaceuticals Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Shuttle Pharmaceuticals Inc (2017–2025)
The table below shows the annual total liabilities of Shuttle Pharmaceuticals Inc from 2017 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $8.22 Million | +357.48% |
| 2024-12-31 | $1.80 Million | -5.21% |
| 2023-12-31 | $1.90 Million | +94.32% |
| 2022-12-31 | $975.68K | -57.20% |
| 2021-12-31 | $2.28 Million | +2.03% |
| 2020-12-31 | $2.23 Million | +276.27% |
| 2018-12-31 | $593.82K | +46.39% |
| 2017-12-31 | $405.65K | -- |
About Shuttle Pharmaceuticals Inc
Shuttle Pharmaceuticals Holdings, Inc., a clinical stage pharmaceutical company, develops novel therapies to treat cancers. It owns a pharmaceutical software artificial intelligence (AI) driven platform for molecular discovery and early-stage drug development. The company was founded in 2012 and is headquartered in Gaithersburg, Maryland.